Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Chronic Myelogenous Leukemia:

Treatment of chronic myelogenous leukemia. Kujak C et al. Am J Health Syst Pharm. (2016)

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Barrett AJ et al. Blood. (2015)

[Chronic myelogenous leukemia: diagnosis and treatment]. Demeter J et al. Orv Hetil. (2016)

Search results

Items: 1 to 20 of 23470

1.

Dynamics of Minimal Residual Disease in Neuroblastoma Patients.

Uemura S, Ishida T, Thwin KKM, Yamamoto N, Tamura A, Kishimoto K, Hasegawa D, Kosaka Y, Nino N, Lin KS, Takafuji S, Mori T, Iijima K, Nishimura N.

Front Oncol. 2019 Jun 4;9:455. doi: 10.3389/fonc.2019.00455. eCollection 2019. Review.

2.

[Effect of Stably Down-regulating FMI Expression of K562 Cells on Sensitivity of K562 cells to Imatinib Mesylate].

Han YH, Zhang HX, Hong F, Yu D, Hu CY, Sun Q, Zeng LY, Li ZY, Yan ZL, Xu KL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Jun;27(3):708-716. doi: 10.19746/j.cnki.issn.1009-2137.2019.03.011. Chinese.

PMID:
31204920
3.

Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction.

Patel G, Pancholy N, Thomas L, Rai A, Kher A, Peters C, Amin A, Patel TM, Pancholy S.

Am J Cardiol. 2019 May 21. pii: S0002-9149(19)30515-6. doi: 10.1016/j.amjcard.2019.04.049. [Epub ahead of print]

PMID:
31196560
4.

New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents.

de Melo ACC, Santana JMSVP, Nunes KJRC, Rodrigues BL, Castilho N, Gabriel P, Moraes AH, Marques MA, de Oliveira GAP, de Souza ÍP, Terenzi H, Pereira-Maia EC.

Molecules. 2019 Jun 7;24(11). pii: E2154. doi: 10.3390/molecules24112154.

5.

LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukemia cells.

Zhang F, Ni H, Li X, Liu H, Xi T, Zheng L.

FEBS Lett. 2019 Jun 10. doi: 10.1002/1873-3468.13480. [Epub ahead of print]

PMID:
31180580
6.

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.

Song GJ, Rahman MH, Jha MK, Gupta DP, Park SH, Kim JH, Lee SH, Lee IK, Sim T, Bae YC, Lee WH, Suk K.

Front Pharmacol. 2019 May 20;10:543. doi: 10.3389/fphar.2019.00543. eCollection 2019.

7.

Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.

Fowlkes S, Murray C, Fulford A, De Gelder T, Siddiq N.

Can Oncol Nurs J. 2018 Oct 1;28(4):262-268. doi: 10.5737/23688076284262268. eCollection 2018 Fall.

8.

Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs.

Fowlkes S, Murray C, Fulford A, De Gelder T, Siddiq N.

Can Oncol Nurs J. 2018 Oct 1;28(4):276-281. doi: 10.5737/23688076284276281. eCollection 2018 Fall.

9.

Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia.

Ghosn Y, Kamareddine MH, Tawk A, Elia C, El Mahmoud A, Terro K, El Harake N, El-Baba B, Makdessi J, Farhat S.

Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819853241. doi: 10.1177/1533033819853241.

10.

Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell.

Ragg S, Zehentner BK, Loken MR, Croop JM.

Pediatr Blood Cancer. 2019 May 28:e27829. doi: 10.1002/pbc.27829. [Epub ahead of print]

PMID:
31136068
11.

PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells.

Ivanova ES, Tatarskiy VV, Yastrebova MA, Khamidullina AI, Shunaev AV, Kalinina AA, Zeifman AA, Novikov FN, Dutikova YV, Chilov GG, Shtil AA.

Int J Oncol. 2019 Jul;55(1):289-297. doi: 10.3892/ijo.2019.4801. Epub 2019 May 14.

PMID:
31115499
12.

Erratum: BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia.

[No authors listed]

Clin Case Rep. 2019 May 10;7(5):1114. doi: 10.1002/ccr3.2118. eCollection 2019 May.

13.

[Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy].

Yu L, Qin YZ, Lai YY, Shi HX, Huang XJ, Jiang Q.

Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):281-287. doi: 10.3760/cma.j.issn.0253-2727.2019.04.004. Chinese.

PMID:
31104438
14.

Validation of a Drosophila model of wild type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: An effective platform for treatment screening.

Al Outa A, Abubaker D, Bazarbachi A, El Sabban M, Shirinian M, Nasr R.

Haematologica. 2019 May 17. pii: haematol.2019.219394. doi: 10.3324/haematol.2019.219394. [Epub ahead of print]

15.

Role of SIRT1 in hematologic malignancies.

Huang FT, Sun J, Zhang L, He X, Zhu YH, Dong HJ, Wang HY, Zhu L, Zou JY, Huang JW, Li L.

J Zhejiang Univ Sci B. 2019 May;20(5):391-398. doi: 10.1631/jzus.B1900148.

PMID:
31090265
16.

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?

de Almeida Filho TP, Maia Filho PA, Barbosa MC, Dutra LLA, Castro MF, Duarte FB, Quixadá ATS, Lemes RPG.

Hematol Transfus Cell Ther. 2019 Apr - Jun;41(2):114-118. doi: 10.1016/j.htct.2018.10.003. Epub 2019 Feb 16.

17.

Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon.

Andrade AR, Leitão DDS, Paz IP, Evangelista TR, Mello VJ, Hamoy M.

Hematol Transfus Cell Ther. 2019 Apr - Jun;41(2):106-113. doi: 10.1016/j.htct.2018.09.006. Epub 2019 Feb 16.

18.

Patterns of bone marrow aspiration confirmed hematological malignancies in Eritrean National Health Laboratory.

Belai N, Ghebrenegus AS, Alamin AA, Embaye G, Andegiorgish AK.

BMC Hematol. 2019 May 2;19:8. doi: 10.1186/s12878-019-0138-3. eCollection 2019. Erratum in: BMC Hematol. 2019 May 31;19:12.

19.

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V.

Oncotarget. 2019 Apr 19;10(29):2793-2809. doi: 10.18632/oncotarget.26876. eCollection 2019 Apr 19.

20.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 May 9. pii: haematol.2018.200220. doi: 10.3324/haematol.2018.200220. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center